Liposomal Aranose Can Change Mrna Cd95/Fas Expression Level in Melanoma Cell Lines

Abstract

Background. Aranose is alkylating antineoplastic agent with cytotoxic and cytostatic properties. Liposomal form of aranose has advantages compared with traditional dosage form. Another alkylating agent, cisplatin, promotes mRNA increase expression level of genes, which control external apoptosis way. Objective. We assume that liposomal form of aranose can change the CD95/Fas, TNFR1, TNFR2, TRAIL, DR3 and DR4/5 expression level in melanoma cell lines mel Kor, mel Z, mel Mtp, mel Mtp-X, mel Ibr, mel Ch, mel Is and mel R. Materials and methods. There are two forms of aranose were used in this work: liposomal form and traditional diluted form for injection. Melanoma cell lines were incubated with both forms. We used RQ PCR to evaluate mRNA expression mRNA expression of DR3, DR4/5, CD95/Fas, TNFR1, TNFR2 and TRAIL relatively gene ABL. Results. CD95/FAS mRNA expression level was most changeable. Liposomal aranose increase CD95/FAS expression level in mel Ibr and mel Mtp-X cell lines and reduced CD95/FAS expression level in mel Ch and mel Is. Conclusion. Thus, liposomal aranose can change mRNA CD95/FAS expression level in melanoma cell lines. Using this process, liposomal form can affect the apoptotic cell death of melanoma.

The influence of drug formulations on the expression of MDM2 and NFkB1 mRNA in the melanoma cell lines

“…В исследованиях было показано, что липосомальная араноза in vitro оказывает воздействие на клеточные линии, устойчивые к аранозе-лио [24]. Было обнаружено, что лекарственные формы аранозы по-разному воздействуют на клетки меланомы [25,26].…”

The influence of aranoza drug formulations and «empty» liposomes on the expression of PD-L1 и PD-L2 in human melanoma cell lines

“…В исследованиях [26,27] было показано, что липосомальная араноза in vitro оказывает воздействие на клеточные линии, устойчивые к аранозе-лио. Было обнаружено, что лекарственные формы аранозы по-разному воздействуют на клетки меланомы [28,29].…”